Election of new board members
The meeting resolved, in accordance with the nomination committee's proposal, (i) that the number of board members shall be six, with no deputy members, and (ii) to elect
Fees for the board and committees
The meeting resolved, in accordance with the nomination committee's proposal, that the remuneration resolved by the Annual General Meeting 2023 to the board members elected by the Annual General Meeting 2023 for the period from their election to the Extraordinary General Meeting shall be paid in proportion to the length of their respective terms of office. The meeting further resolved that remuneration for work within the board to each of the current board members elected by the Annual General Meeting 2023 and to each of the newly elected board members shall be
Furthermore, it was resolved that the Chair of the
Equity incentive program for the Company's management and key personnel
The meeting resolved, in accordance with the board of directors' proposal, to adopt an equity incentive program for the Company's management and key personnel, including a resolution to issue not more than 2,597,234 warrants to ensure the delivery of shares to the participants and for hedging of social security costs. The incentive program entails that the participants will be granted options which entitles the holder to purchase shares in the company at a pre-determined exercise price corresponding to 100 percent of the volume-weighted average price of the
Equity incentive program for the Company's board of directors
The meeting resolved, in accordance with the nomination committee's proposal, to adopt an equity incentive program for the Company's board of directors, including a resolution to issue not more than 649,309 warrants to ensure the delivery of shares to the participants and for hedging of social security costs. The incentive program entails that the participants will be granted options which entitles the holder to purchase shares in the company at a pre-determined exercise price corresponding to 100 percent of the volume-weighted average price of the
For more information, please contact:
President and Chief Executive Officer
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
The information was submitted for publication, through the agency of the contact persons set out above, at [11.30] CET on 21st
https://news.cision.com/immunovia-ab/r/bulletin-from-the-extraordinary-general-meeting-in-immunovia-ab,c3879799
https://mb.cision.com/Main/13121/3879799/2443940.pdf
(c) 2023 Cision. All rights reserved., source